First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!

We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about our therapeutic programs and project advancements in our Annual Report 2016.

More Info

Hematological cancers 
affect adults and children alike.

MorphoSys is developing several blood cancer programs.

More Info

Solid tumors can occur in 
several organs of the human body.

MorphoSys and its partners are working on a broad portfolio of new therapies.

More Info

MorphoSys's vision

MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

learn more about the company

23/04/2018
MorphoSys Announces Closing of Nasdaq IPO through an ADS Offering and...
18/04/2018
MorphoSys Announces Pricing of Initial Public Offering of American...
18/04/2018
Ad hoc: MorphoSys Resolves a Capital Increase to Implement the Offering of...
10/04/2018
MorphoSys Nominates New Candidates for Supervisory Board
09/04/2018
Ad hoc: MorphoSys Announces Launch of American Depositary Shares (ADS)...
06/04/2018
MorphoSys Announces Approval of Tremfya(R) (Guselkumab) for the Treatment...
05/04/2018
MorphoSys Announces Approvals for Tremfya(R) (Guselkumab) for the...
22/03/2018
Ad hoc: MorphoSys Files Registration Statement in the United States for a...
14/03/2018
Clinical Data Presentations at AAT in Alzheimer's Disease
13/03/2018
MorphoSys Reports Updated Data from L-MIND Study of MOR208 plus...

March 13, 2018
Webcast & Conference Call MorphoSys AG Year-End Results 2017

Full details

 

 

 

 

Simon Moroney, CEO
on Strategy and Goals